In a closely watched pharmaceutical patent appeal, the United States Court of Appeals for the Federal Circuit delivered a decisive ruling on March 11, 2024, affirming the unpatentability of Alzheon, Inc.’s patent covering isotope-enriched 3-amino-1-propanesulfonic acid (3-APS) derivatives—compounds central to Alzheimer’s disease treatment research. Case No. 22-2232, Risen (Suzhou) Pharma Tech Co., Ltd. v. Alzheon, Inc., concluded after 537 days of appellate proceedings with the Federal Circuit upholding a cancellation of Alzheon’s patent rights.

For pharmaceutical patent attorneys, in-house IP counsel, and R&D teams developing CNS therapeutics, this outcome carries significant strategic weight. The ruling reinforces the formidable challenge patentees face when defending isotope-labeled compound patents against invalidity attacks—particularly where prior art and patentability arguments converge at the Federal Circuit level. This pharmaceutical patent infringement and validity dispute offers critical lessons on prosecution strategy, IPR risk management, and freedom-to-operate planning in the competitive Alzheimer’s drug development space.

The cancellation of Alzheon’s ‘323 patent has direct competitive consequences in the Alzheimer’s therapeutics market, where isotope-enriched 3-APS derivatives represent a specific strategy to differentiate next-generation compounds from tramiprosate’s established prior art. With the patent invalidated, Risen and potentially other manufacturers gain greater freedom to develop or commercialize 3-APS-related compounds without risk of infringement under this specific patent.

More broadly, this case reflects a broader litigation trend: Chinese pharmaceutical companies are no longer passive recipients of U.S. patent enforcement but are proactively challenging patents that could impede their commercial or licensing strategies. This mirrors patterns seen in the biosimilar space and signals increasing sophistication in IP strategy among Asia-Pacific pharmaceutical companies.

For the CNS drug development sector, the ruling may encourage further validity challenges against isotope-enriched compound patents held by clinical-stage companies, potentially affecting licensing negotiations, partnership valuations, and investor assessments of patent portfolio strength in the Alzheimer’s drug pipeline.

Aperçu du dossier

Les parties

Le brevet en cause

At the center of this dispute is U.S. Patent No. 10,472,323 B2 (Application No. 15/476,255), entitled “Isotope-Enriched 3-Amino-1-Propanesulfonic Acid Derivatives and Uses Thereof.” The patent claims isotope-enriched variants of 3-APS compounds, leveraging deuterium or other isotopic substitutions to potentially improve metabolic stability and pharmacokinetic profiles—a common strategy in modern drug development to extend compound IP life cycles beyond base molecule exclusivity.

• • US 10,472,323 B2 — Isotope-enriched 3-amino-1-propanesulfonic acid derivatives

The Accused Product and Commercial Significance

The invalidity action centered on whether Alzheon’s claimed isotope-enriched derivatives met the statutory requirements for patentability. Given the commercial stakes surrounding Alzheimer’s therapeutics—a multi-billion-dollar market with significant unmet medical need—control over isotope-enriched 3-APS compound IP carries substantial licensing and exclusivity value.

Représentation juridique

• • Plaintiff (Risen): Quinn Emanuel Urquhart & Sullivan, LLP — James M. Glass, Mark YehKai Tung, Sean Gloth
• • Defendant (Alzheon): Finnegan, Henderson, Farabow, Garrett & Dunner, LLP — Drew Christie, Jason Lee Romrell, Jessica L. Roberts, Joshua Goldberg, Mark J. Feldstein, Yieyie Yang

Both firms are among the most prominent in U.S. patent litigation, signaling the high stakes each party assigned to this proceeding.

Chronologie du litige et historique de la procédure

The appeal was filed on September 21, 2022, before the Court of Appeals for the Federal Circuit, the specialized appellate court with exclusive jurisdiction over U.S. patent matters. The case reached the Federal Circuit following a lower-level patentability proceeding—consistent with the verdict cause categorized as an “Invalidity/Cancellation Action”—most likely originating from a USPTO Patent Trial and Appeal Board (PTAB) inter partes review (IPR) or post-grant review (PGR) proceeding.

The appellate phase spanned 537 days, closing on March 11, 2024. This duration is within the typical range for Federal Circuit patent appeals, which commonly require 18 to 24 months from docketing through final disposition, accounting for briefing schedules, oral argument scheduling, and panel deliberation. The case was adjudicated in the District of Columbia circuit region, consistent with Federal Circuit venue.

No specific information regarding district court trial proceedings, claim construction orders, or summary judgment rulings was disclosed in the available case record. The Federal Circuit’s affirmance of the unpatentability finding indicates the appellate panel found no reversible error in the underlying tribunal’s legal analysis or factual determinations.

Le verdict et l'analyse juridique

Résultat

The Federal Circuit affirmed the finding of unpatentability, resulting in the cancellation of U.S. Patent No. 10,472,323 B2. No damages were at issue, as this proceeding was an invalidity/cancellation action rather than an infringement suit seeking monetary relief or injunctive relief against a product launch.

Analyse des causes du verdict

The basis of termination was determined to be unpatentability—meaning the claims of the ‘323 patent failed to satisfy one or more statutory requirements under 35 U.S.C., most likely novelty (§102), non-obviousness (§103), or written description/enablement (§112). In cases involving isotope-labeled compounds, the most frequently litigated patentability challenge is obviousness: challengers typically argue that isotopic substitution of a known compound is a routine technique well within the skill of an ordinary medicinal chemist, yielding predictable results without inventive contribution.

Alzheon’s defense—represented by the highly experienced Federal Circuit practice group at Finnegan Henderson—was insufficient to overcome the invalidity showing on appeal. The Federal Circuit’s affirmance signals that the underlying tribunal’s factual findings on patentability, which are reviewed for substantial evidence, were adequately supported by the record.

Specific claim construction rulings, expert testimony details, or the precise statutory grounds for unpatentability were not disclosed in the available case data. Practitioners seeking full analytical detail should consult the Federal Circuit’s opinion directly via the court’s official docket.

Signification juridique

This ruling contributes to a growing body of Federal Circuit precedent scrutinizing the patentability of isotope-enriched pharmaceutical compounds. The decision underscores that deuterium substitution and isotope enrichment strategies, while commercially valuable, face meaningful invalidity risk when prior art discloses the base compound and isotopic labeling techniques are established in the art.

For patent prosecutors drafting claims around isotope-enriched drug molecules, the case reinforces the importance of establishing concrete, unexpected results—improved efficacy, reduced toxicity, superior bioavailability—rather than relying on structural novelty alone.